Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Unresectable Metastatic Colorectal Cancer Clinical Trial

Official title:
An Open-label, Phase Ib Study to Assess the Safety and Clinical Activity of CYAD-101 Administered Concurrently With FOLFOX Chemotherapy, Followed by Pembrolizumab Treatment, in Patients With Metastatic Colorectal Cancer

Status Recruiting

Clinical Trial Summary

The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.

Clinical Trial Description

This Study aims to provide insight into whether CYAD-101 administration concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment might be a treatment option for patients with unresectable metastatic colorectal cancer ;

Study Design

Related Conditions & MeSH terms

Colorectal Neoplasms
Unresectable Metastatic Colorectal Cancer

Clinical Trial Details

NCT number	NCT04991948
Study type	Interventional
Source	Celyad Oncology SA
Contact	Celyad Oncology Medical Monitor, MD, PhD
Phone	+3210394100
Email	clinicaltrials@celyad.com
Status	Recruiting
Phase	Phase 1
Start date	November 22, 2021
Completion date	May 25, 2038

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05068206` - A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx	Phase 2
Not yet recruiting	`NCT04131803` - Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer	N/A
Recruiting	`NCT03692429` - alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells	Phase 1
Recruiting	`NCT06107413` - Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab	Phase 2
Completed	`NCT01802684` - OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT04160416` - mXELOXIRI Combined With Molecular Targeted Drug in mCRC	Phase 2
Recruiting	`NCT04866108` - A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy	Phase 2